H
Haohao Li
Researcher at Zhengzhou University
Publications - 5
Citations - 41
Haohao Li is an academic researcher from Zhengzhou University. The author has contributed to research in topics: Medicine & Kinase. The author has an hindex of 1, co-authored 1 publications receiving 28 citations.
Papers
More filters
Journal ArticleDOI
Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
TL;DR: GAS5 was downregulated in esophageal cancer patients compared to healthy controls, and GAS5 overexpression suppressed proliferation and migration of esophagal cancer cells by inactivating the PI3K/AKT/mTOR pathway.
The role of SPI1-TYROBP-FCER1G network in oncogenesis and prognosis of osteosarcoma, and its association with immune infiltration
TL;DR: This study identified the downregulated SPI1-TYROBP-FCER1G network in OS, which were significantly enriched in immune-related functions and defined a two-gene signature that can predict poorer OS overall survival and the attenuated immune infiltration when downregulated.
Journal ArticleDOI
The role of SPI1-TYROBP-FCER1G network in oncogenesis and prognosis of osteosarcoma, and its association with immune infiltration
Journal ArticleDOI
Bibliometric and visual analysis of RAN methylation in cardiovascular disease
TL;DR: Zhang et al. as discussed by the authors visualized the results and research trends of global RNA methylation in CVD using CiteSpace 1.6.R4 advanced and VOSviewer 1.18.
Journal ArticleDOI
Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroesophageal junction cancer (GC/EGJC): Preliminary results of a phase 2, single-arm trial.
Chunlin Zhao,Xiangrui Meng,Zhengzheng Shan,Jianwu Jiang,Haohao Li,Junfeng Sun,Chao Ding,Jin Xia,Zhiqiang Liu,Feng Wang +9 more
TL;DR: In this article , Tislelizumab and trastuzumab were combined with standard chemotherapy in the perioperative period of resectable gastric adenocarcinoma.